Showing results (201-210 of 286) with videos related to
Sort By:
Pageof 29
Cancer|November 15, 1996
Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapyF O Recio, M S Piver, R E Hempling, et al.Gynecologic Oncology|June 1, 2000
Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient miceD F Silver, R E Hempling, M S Piver, et al.Gynecologic Oncology|December 1, 1996
Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancerJ M Goldberg, M S Piver, R E Hempling, et al.Cancer|January 15, 1980
Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinomaM S Piver, J J Barlow, J R Lurain, et al.European Journal of Gynaecological Oncology|January 1, 1994
Lack of activity of 5-fluorouracil plus mitomycin-C as salvage therapy in cisplatin-resistant epithelial ovarian cancer: results of a phase II trialR E Hempling, M S Piver, T R Baker, et al.JAMA|March 29, 1976
Oral contraceptive patient information. A questionnaire study of attitudes, knowledge, and preferred information sourcesL Fleckenstein, P Joubert, R Lawrence, et al.Obstetrics and Gynecology|June 1, 1997
Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control studyR E Hempling, C Wong, M S Piver, et al.Gynecologic Oncology|March 1, 1988
Serum alpha 1-acid glycoprotein in epithelial ovarian cancerM S Piver, M Moyer, K Diakun, et al.Obstetrics and Gynecology|March 13, 1999
Perineal talc exposure and subsequent epithelial ovarian cancer: a case-control studyC Wong, R E Hempling, M S Piver, et al.Experimental Cell Biology|January 1, 1987
Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusionsH J Allen, C Porter, M Gamarra, et al.Pageof 29